Quotes 5-day view Delayed Nasdaq
08/15/2022
08/16/2022
08/17/2022
08/18/2022
08/19/2022
Date
17.18(c)
17.54(c)
17.4(c)
18.13(c)
18.16
Last
266 998
245 133
389 536
427 683
182 184
Volume
+2.87%
+2.10%
-0.80%
+4.20%
+0.17%
Change
Estimated financial data (e) (USD)
Sales 2022
107 M
-
-
Net income 2022
-65,5 M
-
-
Net cash position 2022
58,8 M
-
-
P/E ratio 2022
-9,33x
Yield 2022
-
Sales 2023
130 M
-
-
Net income 2023
-54,7 M
-
-
Net cash position 2023
30,3 M
-
-
P/E ratio 2023
-11,5x
Yield 2023
-
Capitalization
622 M
622 M
-
EV / Sales 2022
5,25x
EV / Sales 2023
4,54x
Nbr of Employees
352
Free-Float
98,2%
SI-BONE, Inc. is a medical device company. The Company is focused on the development of implantable devices used in the surgical treatment of sacro-pelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the...
All news about SI-BONE, INC.
08/18 INSIDER SELL : Si-boneMT
08/09 SI-BONE, INC. Management's Discussion and Analysis of Financial Condition and Results
.. AQ
08/09 Morgan Stanley Raises SI-Bone's Price Target to $21 From $18, Maintains Overweight Rati.. MT
08/09 Needham Adjusts SI-Bone's Price Target to $24 From $28, Reiterates Buy Rating MT
08/08 SI BONE : Reports Financial Results for the Second Quarter 2022 - Form 8-KPU
08/08 SI BONE : June 2022 Investor PresentationPU
08/08 SI-BONE : Q2 Earnings SnapshotAQ
08/08 TRANSCRIPT : SI-BONE, Inc., Q2 2022 Earnings Call, Aug 08, 2022CI
08/08 Earnings Flash (SIBN) SI-BONE Posts Q2 Revenue $25.6M MT
08/08 SI-BONE, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June.. CI
08/08 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022 AQ
08/08 SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022 CI
07/18 SI-BONE To Report Second Quarter 2022 Financial Results on August 8, 2022 AQ
07/18 SI-BONE To Present at The Canaccord Genuity 42nd Annual Growth Conference 2022 AQ
07/15 Morgan Stanley Lowers SI-Bone's Price Target to $18 From $22, Overweight Rating Kept MT
News in other languages on SI-BONE, INC.
Analyst Recommendations on SI-BONE, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SI-BONE, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
7
Last Close Price
18,13 $
Average target price
24,57 $
Spread / Average Target
35,5%
Please enable JavaScript in your browser's settings to use dynamic charts.